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Biological rationale for the use of DNA
methyltransferase inhibitors as new strategy for
modulation of tumor response to chemotherapy
and radiation
Giovanni L Gravina1,2*, Claudio Festuccia2, Francesco Marampon1,2,3, Vladimir M Popov3, Richard G Pestell3,
Bianca M Zani2, Vincenzo Tombolini1,2
Abstract
Epigenetic modifications play a key role in the patho-physiology of many tumors and the current use of agents
targeting epigenetic changes has become a topic of intense interest in cancer research. DNA methyltransferase
(DNMT) inhibitors represent a promising class of epigenetic modulators. Research performed yielded promising
anti-tumorigenic activity for these agents in vitro and in vivo against a variety of hematologic and solid tumors.
These epigenetic modulators cause cell cycle and growth arrest, differentiation and apoptosis. Rationale for com-
bining these agents with cytotoxic therapy or radiation is straightforward since the use of DNMT inhibitor offers
greatly improved access for cytotoxic agents or radiation for targeting DNA-protein complex. The positive results
obtained with these combined approaches in preclinical cancer models demonstrate the potential impact DNMT
inhibitors may have in treatments of different cancer types. Therefore, as the emerging interest in use of DNMT
inhibitors as a potential chemo- or radiation sensitizers is constantly increasing, further clinical investigations are
inevitable in order to finalize and confirm the consistency of current observations.
The present article will provide a brief review of the biological significance and rationale for the clinical potential of
DNMT inhibitors in combination with other chemotherapeutics or ionizing radiation. The molecular basis and
mechanisms of action for these combined treatments will be discussed herein.
A significant number of tumors are classified as poorly
or non-responsive to therapeutic drugs or radiotherapy.
Increasing the chemotherapeutic dosage or radiation
dose not only fails in improving the therapeutic
response, but it also contributes to the development of
side effects and resistance to therapy. An ideal strategy
would consist of the identification of anticancer agents
able to act synergistically with standard treatments such
as radiotherapy and chemotherapy, which would result
in triggering the cell death preferentially in tumor cells.
Many patients with neoplastic diseases exhibit hyper-
methylation of cytosine residues in gene promoters
which induce silencing of key tumor suppressor genes.
Since methylation of CpG islands occurs infrequently in
normal cells, the modulation of this post-translational
modification may provide a selective tumor-specific
therapeutic target.
The packaging of DNA is critical for many DNA
metabolic processes including transcription, replication
and DNA repair. DNA is normally tightly wrapped
around histone octamers to form nucleosomes. These
primary elements have been traditionally thought as
stable DNA packaging units. However, it is now evident
that they are dynamic structures that can be altered by
different molecular processes [1-3]. These include (i)
incorporation of histone variants, which are thought to
have specialized functions [4], (ii) replacement, reposi-
tioning or, in certain cases, the removal of nucleosomes
by chromatin remodeling complexes, and finally (iii)
post-translational modifications.
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Post-translational modifications include (i) lysine acet-
ylation and deacetylation, (ii) methylation, (iii) serine
phosphorylation and ubiquination and (iv) lysine sumoy-
lation. These modifications play a major role in model-
ing higher-order chromatin conformation and modifying
the DNA accessibility to transcription factors [5,6].
Therefore, such changes are not strictly “genetic,” even
though the specific chromatin patterns are usually
inherited by daughter cells during replication.
In cancer, epigenetic silencing through methylation
occurs just as frequently as mutations or deletions and
leads to aberrant silencing of genes with tumor-suppres-
sor functions [2,3].
Among the post-translational processes, DNA methy-
lation is one of the most extensively characterized epige-
netic modifications and its biological role is to maintain
DNA transcriptionally quiescent, resulting in gene silen-
cing (Figure 1) [7-9]. This process is dependent upon
the action of DNA methyltransferases (DNMTs),
enzymes that catalyze the addition of methyl groups to
the 5’ carbon of the cytosine residues (Figure 1) [7]. Sev-
eral isoforms of DNMTs are present in normal cells as
well as in tumor cells [9-11]. Existing evidence indicates
that DNMT1 appears to be responsible for maintenance
of established patterns of methylated DNA, while
DNMT-3a and -3b seem to mediate de novo DNA
methylation patterns [9-11]. Interestingly DNMT1 alone
is not sufficient for maintenance of abnormal gene
hypermethylation but the cooperation with DNMT3b
must occur for this function [12-14]. In the last years
many different DNMT inhibitors have been developed
(Table 1) and multiple molecular mechanisms by which
DNMT inhibitors induce anti-cancer effects have been
identified. These mechanisms are partially mediated by
the hypomethylation of DNA with cytotoxic effects
documented at higher concentrations [8,15]. The net
effect is the modulation of specific genes involved in cel-
lular processes such as apoptosis, cytostasis, differentia-
tion and tumor angiogenesis [8,15]. Therefore, it is not
surprising that DNMT inhibitors are emerging as pro-
mising class of drugs in cancer treatment, especially in
combination with other agents or with other treatments
like radiotherapy. Even though some DNMT inhibitors
have entered into clinical trials, we currently have lim-
ited understanding of their precise mechanisms of
action, especially when combined with other available
treatments.
The present article will provide a brief review of the
biological significance and scientific rationale for the
clinical potential of DNMT inhibitors in combination
with chemotherapy or radiotherapy.
Combined therapy: Published Experience,
Ongoing Studies and Future directions
The goal of combining different treatments in the man-
agement of cancer is to increase and prolong the
response rate as well as to decrease the toxicity asso-
ciated with each treatment. Two different strategies can
be utilized to achieve these objectives. Treatments may
be combined based on the absence of overlapping or
synergistic toxicities leading to empiric combinations.
A more sound approach is based upon the combination
of treatments with known convergent molecular
mechanisms.
It is well known that epigenetic abnormalities in can-
cer affect a plethora of genes involved in key cellular
pathways including cell cycle control, apoptosis, immune
recognition, angiogenesis tumor invasion and metastasis.
Consistent with the functional diversification of epige-
netic alterations, epigenetic drugs are characterized by
pleiotropic effects which affect key aspects of tumor
biology leading to an overall impairment of the neoplas-
tic potential of tumor cells. These are the reasons that
constitute the rationale for the proposed usage of
DNMT inhibitors as anticancer agents, alone or in com-
bination with other treatments.
DNMT inhibitors and chemotherapy
Despite the promising anticancer activity in haematolo-
gical malignancies [16], early clinical trials showed that
DNMT inhibitors have low anticancer activity and sig-
nificant toxicity as single agent in solid tumors. Recent
studies, however, suggest that low concentrations of
DNMT inhibitors such as 5-Aza and decitabine may act
synergistically when combined with chemotherapy
and contribute to overcoming intrinsic or acquired
Figure 1 Epigenetic modulation of gene expression by post-
translational DNA methylation. Transcriptionally inactive
chromatin is characterized by the presence of methylated cytosines
within CpG dinucleotides (CH3), which is sustained by DNA
methyltransferases (DNMTs).
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chemoresistance [17-19]. These properties are consid-
ered clinically significant as the resistance of tumor cells
to cytotoxic agents remains the major obstacle in che-
motherapeutic-based treatments. The mechanisms
underlying chemoresistance remain in some measure
elusive even though multifactorial mechanisms, includ-
ing epigenetic modifications may drive this mechanism
[20-25]. Therefore, any effort to overcome multi-drug
resistance represents the primary goal in cancer
research. Based on the chemical mechanisms, DNMT
inhibitors act through different mechanisms. Among the
different mechanisms postulated, alterations in differen-
tiation, changes in apoptosis, and induction of a benefi-
cial immune response are considered of main
importance [19]. Finally, the induction of DNA damage
due to the formation of irreversible covalent enzyme-
DNA adducts has also been taken into consideration.
Cell signaling
Cell signaling is a complex system of communication
that coordinates basic cellular activities. Cells perceive
and correctly respond to microenvironment via this
complex system engaging in cellular processes such as,
tissue repair, immunity, as well as normal tissue home-
ostasis. Errors in cell signaling are involved in the devel-
opment as well as in the progression of cancer and
aberrant DNMT activity has been involved in these pro-
cesses. PTEN (phosphatase and tensin homolog deleted
on chromosome ten) is a tumor suppressor gene and its
functional loss has been documented in bladder cancer,
glioblastoma, melanoma and cancers of the prostate,
breast, lung and thyroid [26-30]. This tumor suppressor
gene controls PI3K by preventing the activation of PDK-
1 and Akt (Figure 2). The functional loss of PTEN is
higher than that attributable to LOH of chromosome
10q and post-translational mechanisms, including hyper-
methylation, explain the other part of this phenomenon
[31-34]. Evidence indicates that 5-Aza is a chemosensiti-
zer in prostate cancer [35] and its property seems
mediated by PTEN. After infection with a recombinant
adenovirus containing wild-type PTEN, bladder tumor
cells acquire greater chemosensitivity to the cytotoxic
effect of doxorubicin [36-39]. The chemosensitivity
induced by PTEN is partially mediated by PI3K
and Akt/PKB [40]. Other evidence, in a different
Table 1 Overview of some DNMT inhibitors with their mechanisms of action
Name Chemical nature Mechanism of action
Azacitidine Ribonucleoside
analogue
This drug is a ribonucleoside analogue and it binds to RNA and DNA. This molecule interrupts mRNA
translation and when incorporated into DNA inhibits methylation by trapping DNMTs. At relatively
higher concentrations this drug results in the formation of high levels of enzyme-DNA adducts.
Decitabine Deoxyribonucleoside
analogue
This drug is a deoxyribonucleoside analogue. For this reason, this molecule does not bind to RNA but
only to DNA. When incorporated into DNA inhibits methylation by trapping DNMTs resulting in the
reduced methylation of cytosines in DNA synthesized after drug treatment. When used at relatively
high concentrations this drug results in the formation of high levels of enzyme-DNA adducts,
Zebularine Deoxyribonucleoside
analogue
This drug is a deoxyribonucleoside analogue. For this reason, this molecule does not bind to RNA but
only to DNA. When incorporated into DNA inhibits methylation by trapping DNMTs resulting in the
reduced methylation of cytosines in DNA synthesized after drug treatment. When used at relatively
high concentrations this drug results in the formation of high levels of enzyme-DNA adducts,
(−)-epigallocatechin-
3-gallate
Non-nucleoside
analogue
MG98 Non-nucleoside
analogue
This antisense oligonucleotide targets the 3 UTR of DNMT1 causing a methylation decrease in cell
lines and animal models
RG108 Non-nucleoside
analogue
This small molecule is not incorporated into DNA but i bind to the catalytic site of DNMTs causing
inhibition of DNA methylation
Procainamide Non-nucleoside
analogue
This molecule reduces DNMT1’s affinity
for both DNA and S-adenosyl-methionine causing a decrease in DNA methylation
Figure 2 DNMT inhibitors and PTEN/PI3K/Akt pathway. PTEN/
PI3K/Akt pathway physiologically plays a key role in the control of
many processes essential for the cellular life. The tumor suppressor
PTEN negatively controls the PI3K/Akt pathway and its epigenetic
loss, frequent in cancer cells, leads to the aberrant pathway
activation. DNMT inhibitors restore the PTEN expression by
epigenetic mechanisms.
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experimental model, suggests that the transfection of
TC-32 Ewing sarcoma cells with Akt/PKB inhibits dox-
orubicin-induced apoptosis suggesting that PTEN
increases doxorubicin cytotoxicity through the PI3K sig-
naling pathway. Additional indication of chemosensitiz-
ing properties of PTEN derived from data obtained in
endometrial cancer cells [41]. In this system, PTEN sig-
nificantly enhanced chemosensitivity to doxorubicin.
This effect was associated with the levels of phospho-
Akt/PKB and phospho-Bad (Ser-136), which were
reduced in the PTEN expressing clones. Results from
other studies performed on brain tumors clearly show
that decreasing activity of the PI3K/Akt pathway in
tumor cells with mutant PTEN may contribute to the
increased sensitivity to chemotherapy [42]. Down-regu-
lating the Akt pathway by inducing PTEN also increases
the sensitivity of glioblastoma cells to temozolomide.
DNA base damage
Some kind of acquired or intrinsic chemoresistance may
be epigenetic in nature and operate at DNA mismatch
repair level [43-48]. Interestingly, suppression of a DNA
mismatch repair mechanism seems [49] to act in concert
with other independent DNA mismatch repair machi-
neries [50,51], resulting in drug resistance and genetic
instability [52]. The suppression of DNA mismatch repair
mechanism can occur at epigenetic level and in the
absence of heritable inactivating mutations. Demethylating
agents have been shown to reverse drug resistance to alky-
lating agents in some preclinical models of ovarian and
colorectal cancer [53]. This process may happen through
up-regulation of MLH1, and is mediated by 5-Aza treat-
ment, which sensitizes tumor cells to cisplatin. However,
5-Aza treatment does not sensitize MLH1 mutant cells to
cisplatin, indicating that MLH1 gene reactivation is
required for the sensitization [53,54]. If MLH1 reactivation
is required for the sensitization to cisplatin, several con-
cerns still exist about the value of epigenetic modulation
of DNA repair genes in inducing chemosensitization. It is
well known that MGMT, another DNA repair mediator, is
frequently epigenetically silenced [55]. Consistent with its
role in protecting the genome from G to A transitions,
induced by alkylating agents, MGMT inactivation through
its promoter hypermethylation has been associated with G
to A mutations in k-ras and p53 genes in colorectal cancer
[56,57]. Even though DNMT inhibitors, such as 5-Aza and
decitabine, have proven effective in re-expressing MGMT
in cancer cells, the clinical advantage of the restored
MGMT expression is doubtful [58-60] since tumors with
the unmethylated promoter of MGMT gene appear signif-
icantly less susceptible to the cytotoxic effects of alkylating
drugs [56,57,60].
Although the biological effects of DNMT inhibitors on
methylation and demethylation status of DNA mismatch
repair genes have been extensively studied, DNA
damage-related sequelae of these agents is still not fully
understood. DNA Double Strand Breaks (DSBs) are the
most cytotoxic DNA lesions. One-ended DSBs can be
formed via collapse of a replication fork at the site of a
blocking DNA lesion [61-64]. Given that DNMT inhibi-
tors, as well as some chemotherapeutics, create irreversi-
ble covalent DNA-enzyme adducts, the convergence of
these phenomena may be one possible mechanism by
which these two agents synergize and induce cytotoxicity
[65,66]. Several reports indicate that 5-Aza, decitabine
and zebularine induce DSB responses followed by
induced apoptosis. These responses may be mediated via
ATR or ATM, which are two key mediators promoting
DNA DSB response signalling [67-69]. Given that the
DSB responses induced by 5-Aza and doxorubicin engage
in distinct signaling pathways, the combination of these
two agents may cooperate and synergistically induce cell
death [70]. The induction of DNA damage response by
Chk2 and p53 phosphorylation could be another
mechanism by which DNMT inhibitors induce DNA
damage-related sequelae and cooperate with chemothera-
peutics [71-75]. In this regard, some studies revealed that
decitabine may be cytotoxic against both p53 wild-type
and p53 mutant containing tumor cells, suggesting that
p53 function is not always required in order to mediate
the apoptotic process of DNMT inhibitors. Finally, it has
been demonstrated that these agents can induce DNA
damage in a dose-dependent manner, while the degree
and the kind of DNA damage induced parallels the
amount of incorporated DNMT inhibitor [76]. This may
be an important cooperative mechanism since when the
cytotoxic effect of DNMT inhibitors takes place in close
proximity of a single- or double-strand break induced by
chemotherapeutics the damage may be lethal.
Apoptosis
Defects in apoptotic pathways promote chemoresistance.
DNMT inhibitors are known to potentiate apoptotic
processes through different pathways. Evidence suggests
that the induction of TRAIL by decitabine is critical for
sensitizing breast cancer cells to Adriamycin. The silen-
cing of TRAIL decreases caspase activation and abro-
gates chemosensitization mediated by decitabine. Several
mechanisms by which DNMT inhibitors induce TRAIL
have been postulated. One of the possible mechanisms
is the activation of TRAIL gene expression [77,78].
Additional evidence suggests that the induction of
TRIAL by decitabine is mediated by the increase in the
half-life of TRAIL protein [78] or by the induction of
TRAIL via Akt. It is known that the PI3K inhibitor
wortmannin can induce TRAIL [79], and that the over-
expression of the active form of Akt can abolish TRAIL
induction mediated by wortmannin. In agreement with
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this evidence, Akt, working as a negative modulator of
TRAIL, is modulated by 5-Aza resulting in a decrease of
phosphorylated Akt and enhanced TRAIL expression.
If TRAIL plays a key role in the apoptotic process
mediated by DNMT inhibitors, other investigators sug-
gest that the methylation in the promoter region of cas-
pase 8 and caspase 9 is another well known mechanism
by which tumors acquire chemoresistance. Mechanistic
studies indicate that decitabine induces caspase-8 and
caspase-9 and sensitizes tumor cells to TRAIL, etopo-
side, cisplatin [80,81] and paclitaxel [82].
Overexpression of the Activator protein 2a (AP-2a) is
another mechanism through which DNMT inhibitors
may induce apoptosis and influence chemosensitivity.
AP-2a is a sequence-specific DNA-binding transcription
factor that is required for regulation of many genes
involved in many biological functions [83-85]. Growth
inhibitory activity of AP-2a is mediated through direct
interaction with p53 [86] and the overexpression of this
transcription factor induces cell cycle arrest and apopto-
sis [87,88]. Epigenetic targeting of AP-2a inhibits tumor
proliferation and increases tumor cell death [89]. This
acquires a meaningful clinical significance considering
that 75% of invasive breast tumors have epigenetically
silenced AP-2a. Therefore, the use of DNMT inhibitors
may provide the unique opportunity for modifying the
chemosensitivity of breast cancer containing hyper-
methylated and silenced AP-2a [90-95].
Oxidative stress
Agents inducing oxidative stress determine cellular
damage by reactive oxygen intermediates (ROI). Small
amounts of ROI may act as signalling molecules but if
ROI production exceeds the endogenous intracellular
antioxidative capacities [96,97] an oxidative stress occurs
[98] resulting in cell death. Increased ROI levels contri-
bute to the development of chemoresistance and grow-
ing evidence supports a role of epigenetic processes in
ROS-induced generation of oxidative stress [99-105].
The proto-oncogene AP-1 plays a central role in the
control of cellular response to oxidative stress [106-109].
It modulates the expression of target genes involved in
protective and/or reparative cellular responses to the
damaging effects of oxidative stress [110-113]. Experi-
mental data suggest that H2O2 stress-resistant tumor
cells have increased AP-1 DNA-binding activity and are
resistant to the damaging effects of chemotherapeutic
agents [114]. The inhibition of the AP-1 complex
reverses the multimodality resistance phenotype
(MMRP) in response to oxidative stress through the
inhibition of Fos activity [114]. Other studies have
expanded these observations showing that DNMT1, a
downstream target of Fos, is upregulated in chemoresis-
tant tumor cells [114]. These results indicate that the
epigenome may play a critical role to oxidative stress
and highlights a potential role of DNMT1 activity abro-
gation as a potential molecular target in chemoresistant
tumor cells. This evidence has been further confirmed
showing that the selective silencing of DNMT1 and
DNMT3b greatly reduces the chemoresistance of tumor
cells overexpressing DNMTs isoenzymes [115].
DNMT inhibitors and radiotherapy
The therapeutic index of radiotherapy can be improved
by chemical agents that sensitize cancer cells to the
toxic effects of ionizing radiation. Radiotherapy and sys-
temic agents may interact through two main modalities
(Figure 3). In the first modality, radiotherapy acts locor-
egionally and systemic agents act against micro-metas-
tases without interaction between the treatments. In the
second modality radiotherapy and systemic agents inter-
act within the radiation field increasing tumor cell
death.
Sparse biological data indicate that DNMT inhibitors
may act as radiosensitizers. The meaningful advantage
of DNMT inhibitors as radiosensitizers is that these
agents can induce radiosensitization at concentrations
several times lower than typical plasma levels obtained
when used as single agents [116]. Major interactions
between DNMT inhibitors and radiotherapy may be
postulated. For clearer understanding, the potential bio-
logical mechanisms of cooperation between DNMT
inhibitors and radiotherapy will be discussed separately.
DNA repair
Radiation therapy induces DNA base damage, single-
strand breaks, and double-strand breaks (DSBs). These
structural damages are repairable, except for DSBs,
which are considered lethal [116]. 5-Aza, decitabine and
zebularine lead to protein-DNA adducts and when the
Figure 3 Rationale for combining DNMT inhibitors and
radiation therapy. Spatial and in-field cooperation are the two
modalities of cooperation mechanisms between DNMT and ionizing
radiation.
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cytotoxic effect takes place in close proximity to a radia-
tion-induced single-strand break, the damage may be
significantly more difficult to repair (Figure 4). The
DNA cytosine-C5 methyltransferase (MTase) acts on a
cytosine residue through its recognition sequence by
covalently binding to C6, and then transferring the
methyl group from S-adenosylmethionine to C5. The
covalent protein-DNA linkage is then reversed and the
enzyme dissociates from the DNA. In this context, 5-
Aza, decitabine and zebularine substitution at the target
cytosine interferes with the reaction cycle, which results
in long-lived or irreversible MTase-DNA adducts
[117-121]. The cytotoxic mechanism of DNMT inhibi-
tors has been documented in in vivo models. Results
from these studies suggest that (i) the formation of pro-
tein-DNA adducts mediate decitabine cytotoxicity [122],
(ii) the cytotoxicity levels correlate positively with
MTase levels [123], and (iii) decitabine induce p53 DNA
damage response by MTase-DNA adducts [124-127].
Cell cycle
The radiosensitivity of tumor cells is dependent on the
phase of the cell cycle. Cells in the S-phase are the most
radioresistant, whereas cells in the G2-M phase are the
most radiosensitive. Evidence indicates that DNMT inhi-
bitors synchronize tumor cells preferentially in the G1
or G2/M phase of the cell cycle increasing the efficacy
of radiotherapy (Figure 5). In this way, if administered
concurrently to radiotherapy, the inhibitors may coop-
erate to produce additive or synergistic antitumor
effects. Qui and co-workers demonstrated that low con-
centrations of decitabine synchronize gastric tumor cells
in the G2/M phase of the cell cycle and induce radio-
sensitization [116]. The radiosensitizing effect of this
inhibitor seems to be partly mediated by p53, RASSF1,
and DAPK [116]. RASSF1 and DAPK modulate multiple
apoptotic and cell-cycle checkpoint pathways [128,129]
and the loss of RASSF1 and DAPK expression is docu-
mented in a wide range of human tumors as a result of
silencing, primarily from promoter hypermethylation
[130]. Therefore, the epigenetic modulation of RASSF1
and DAPK shines some light on the synergism between
DNMT inhibitors and radiotherapy in terms of apopto-
tic signaling modulation.
Angiogenesis
Induction of anti-angiogenic activity in radiotherapy as a
result of combined treatments with DNMT inhibitors is
backed by a clear rationale. Common in many cancers
hypoxia has been indicated as a marker of aggressive
clinical behaviour, poor prognosis and unsatisfying
radiation response. Therefore, any compound able to
increase perfusion and oxygenation reduces the radiore-
sistant hypoxic areas counteracting the onset of hypoxic
and radioresistant clones.
Experimental data suggest that many key modulators of
angiogenesis are under epigenetic control. The promoter
of von Hippel-Lindau (VHL) tumor suppressor gene is
hypermethylated and its absence leads to a failure in
degradation of hypoxia inducible factor (HIF)-1 whose
accumulation favors tumor angiogenesis [131]. This aber-
rant pathway has been successfully inactivated by decita-
bine, which in addition to restoring VHL expression,
down-regulates the vascular endothelial growth factor
(VEGF), the glucose transporter (GLUT)-1 [132] and the
thrombospondin-1 [133]. Radiotherapy has been shown
to kill proliferating endothelial cells. Therefore, any drug
that acts on endothelial cells induces a significant
increase in the cytotoxic effect of radiotherapy decreasing
the levels of angiogenesis. DNMT inhibitors act directly
on activated endothelial cells and inhibit angiogenesis in
vitro and in vivo [132]. Decitabine and its analogue zebu-
larine exhibit significant angiostatic activity. This is
Figure 4 Cooperative cytotoxic mechanism between DNMT
inhibitors and radiation. Ionizing radiation induces DNA base
damage, single-strand breaks, and double-strand breaks (DSBs). All
of these errors can be rapidly repaired except for DSBs, which if not
repaired are considered lethal. The cytotoxic effect of DNMT
inhibitors in close proximity to a radiation-induced single-strand
break can act synergistically to make the defect significantly more
difficult to repair, consequently resulting in the induction of cellular
death.
Figure 5 Cell cycle, DNMT inhibitors and radiosensitivity. The
radiosensitivity of cells is dependent on the phase of the cell cycle.
Cells in the S phase are the most radio resistant, and cells in the
G2-M phase of the cell cycle are the most radiosensitive. DNMT
inhibitors synchronize with the cell cycle of tumor cells increasing
the efficacy of subsequent radiotherapy.
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accompanied by a significant effect on the expression
levels of angiogenesis inhibiting genes (TSP1, JUNB, and
IGFBP3). TSP1 is known to block endothelial cell migra-
tion and to induce apoptosis. JUNB negatively regulates
cell growth by activating p16INK4A and decreasing
cyclin D1 expression [132], while IGFBP3, a key regulator
of cell growth and apoptosis, inhibits VEGF-mediated
HUVEC proliferation [133] and angiogenesis [133]. Re-
expression of these growth-inhibiting genes by DNMT
inhibitors, in activated endothelial cells, may contribute
to a decrease in angiogenesis and improvement in intrin-
sic radiosensitivity.
Apoptosis
Apoptosis is a well known mechanism through which
antitumor agents induce radiosensitization. DNMT inhi-
bitors sensitize tumor cells to apoptosis either by restor-
ing the defective expression of apoptotic effector
proteins, or by re-establishing the expression of signal
transducing/mediators of the apoptotic signals. 5-Aza
restores the expression of DAPK1 in bladder carcinoma
and B-cell lines [134] and the re-expression of DAPK1
in Burkitt’s lymphoma cell lines restores the susceptibil-
ity to IFN-a triggered apoptosis [135]. Similarly, DNMT
inhibitors sensitize NSCLC cells to TRAIL-induced
apoptosis by inducing DAPK1 expression [136]. Besides
DAPK1, 5-Aza and DNMT1 antisense oligonucleotides
are able to restore the sensitivity of cancer cells to IFN-
triggered apoptosis despite the re-expression of the pro-
apoptotic gene RASSF1A and XAF1 which are fre-
quently silenced by epigenetic mechanisms [137,138].
Caspases are not spared from epigenetic inactivation
during tumor transformation. Hypermethylation of cas-
pase-8 promoter leads to its either reduced expression
or complete absence in neoplastic cells resulting in their
resistance to death receptor and drug-induced apoptosis.
However, 5-Aza has proven to be effective in re-estab-
lishing caspase-8 expression in cancer cells, restoring
their sensitivity to TRAIL-, anti-FAS-, and drug-trig-
gered apoptosis [35,139-141].
Cell signaling
DNMT inhibitors are modulators of gene expression
and may increase the expression levels of many key
genes, specifically the ones involved in the radiosensitiz-
ing processes. NF-B is capable of activating a number
of genes involved in stress response, inflammation, and
apoptosis. Loss or inhibition of NF-B activation leads
to radio-sensitization [142-144]. The elevated basal NF-
B activity in certain cancers has been linked with
tumor resistance to chemotherapy and radiation [145].
Together with the assumption that NF-B is capable of
regulating more than 150 effector genes, this transcrip-
tion factor plays a key role in tumor radioadaptive resis-
tance under fractional ionizing radiation. 5-Aza can
rapidly induce inhibition of NF-kB [146]. This effect
may be achieved via down-regulation of pro-survival
and anti-apoptotic (IL-6, IL-6Ra, Bcl-XL) mediators or
abrogating drug-induced NF-kB stress responses
[147,148]. PARP-1 represents the essential transcrip-
tional co-regulator implicated in radiation-induced NF-
B, AP-1, Oct1, and HIF-1a activation [149]. Experi-
mental results demonstrate that the ATM gene is a tar-
get for silencing through aberrant methylation of its
proximal promoter region [150,151]. This epigenetic
event can result in a decreased expression of ATM,
resulting in a radioresistant phenotype consistent with
reduced ATM function. DNMT inhibitors, positively
affecting the levels of ATM, increase radiosensitivity in
human colorectal tumor cell lines. In this regard, the
moderate radiosensitivity displayed by HCT-116 cells
can be increased by 5-azacitidine treatment, correlating
with ATM levels [151].
Epigenetic control of oncogenes: implication for standard
treatments
Global genomic hypomethylation has been documented
in most solid tumors [152-154]. Evidence suggests that
this post-translational mechanism supports tumor devel-
opment [155]. In solid human tumors, a correlation
between global genomic hypomethylation and advanced
tumor stage has been established [154].
Methylation has been primarily considered as a
mechanism for tumor suppressor genes silencing and
genome profiling approaches have identified several
putative tumor suppressor genes silenced by promoter
hypermethylation. So far, unmasked expression of puta-
tive oncogenes has been sporadically reported [156].
Although c-myc was among the very earliest onco-
genes identified and the subject of intense study, it has
nonetheless proven to be an enduring enigma. Results
to date suggest that Myc-Max influences cell growth
and proliferation through direct activation of genes
involved in DNA synthesis, RNA metabolism and cell-
cycle progression [157]. Early studies showed that c-myc
is under epigenetic control and its functional silencing
sensitizes cancer cells to chemotherapy and radiotherapy
[158-160]. These sensitizing effects of c-Myc were pri-
marily achieved by inhibiting MLH1 and MSH2 mis-
match repair proteins [161]. Evidence suggests that
decitabine is unable to modify the expression of c-myc
in gastric cancer [161]. Other evidence, however, suggest
that several proto-oncogenes, whose promoters are
under epigenetic control, may be down-regulated rather
than up-regulated after treatment with epi-drugs [162].
Microarray data revealed that the treatment of myeloma
multiple cells by decitabine and TSA resulted in down-
regulation of several proto-oncogenes such as members
of myc family [162]. Of note, the down-regulation of
these genes was more a response to TSA and
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decitabine/TSA than to decitabine alone. The biological
rationale for this surprising phenomenon is not well
known although this effect may be explained either by a
direct inhibitory action of decitabine and TSA or by an
indirect down-regulation by decitabine and TSA affected
genes [162].
Therefore, these conflicting data may have important
therapeutic implications since demethylation-based ther-
apy can cause unintended effects. It may be possible
that in certain tissues and under selective biological con-
ditions epi-drugs may result in either up- or down-regu-
lation of proto-oncogenes [163]. These concerns may
explain either some of the side effects or the unsuccess-
ful results documented upon demethylation-based ther-
apy in solid tumors.
Response of normal tissues to DNMT inhibitors
The use of DNMT inhibitors raises questions regarding
their potential to epigenetically affect non-cancerous
cells. Therefore, an important issue is a need for a
more complete understanding of the potential benefits
and limitation of DNA methylation as a human cancer
drug target. Conflicting evidence exist in literature
regarding the effect of DNMT inhibitors on normal
cells. Even though well known toxicity profile has been
documented for DNMT inhibitors, especially for
nucleoside analogues such as 5-Aza and decitabine in
the clinical setting (Table 2), many doubts exist about
their long-term safety as well as about their mutagenic
and carcinogenic potential [164]. Some evidence indi-
cate that intraperitoneal injection of 5-Aza at doses
ranging from 2.0 to 2.2 mg/kg for 50-52 weeks in mur-
ine models increased the incidence of malignant
tumors of hematopoietic and lymphoreticular system
as well as of lung, mammary glands and skin [165].
The mutagenic potential of 5-Aza [165] and decitabine
[166] was tested in vitro and in vivo systems. Both ana-
logues increased mutation frequency in L5178Y mouse
lymphoma cells, and mutations were produced in an
Escherichia coli lac-I transgene in colonic DNA of dec-
itabine-treated mice [166]. Decitabine, moreover,
resulted in chromosomal rearrangements in larvae of
fruit flies. The effect of decitabine and 5-Aza on post-
natal development and reproductive capacity was eval-
uated in murine models. Administration of these
inhibitors in male mice resulted in decreased fertility
and loss of offspring during subsequent embryonic and
postnatal development. Decreased weight of the testes
and epididymides with reduced sperm counts were
also detected. Body weights of males and females
exposed in utero to decitabine were significantly
reduced at all postnatal time points. No consistent
effect on fertility was seen when female mice exposed
in utero.
However, if the aforementioned data indicate that
both 5-Aza and decitabine have a tangible toxicity on
normal tissues, recent biological data seem to suggest
that normal cells may interact differently with DNMT
inhibitors than malignant cells. In this regard, some data
suggest that normal cells, dividing at a slower rate than
malignant cells, incorporate less drug than cancer cells
into their DNA resulting in decreased effect on DNA
methylation. Zebularine, a novel DNA methyltransferase
inhibitor, has properties of acting differentially on can-
cerous and normal cells. Continuous treatment with this
drug substantially reduces the growth rate of human
cancer cells with less effect on normal human fibro-
blasts. Growth inhibition in cancer cells was found to be
associated with the induction of p21 which was unmodi-
fied in human fibroblasts. This suggests that the growth-
suppressive potential of zebularine in tumor cells is see-
mingly p21-dependent and its differential effects was
partially due to preferential incorporation of zebularine
into DNA of tumor cells as documented by the uridine/
cytidine kinase activity levels that were generally higher
in cancerous than normal cells. Therefore, the preferen-
tial effects of zebularine in cancer cells in terms of
incorporation into DNA, growth inhibition, demethyla-
tion, and depletion of DNMTs are probably due to dif-
ferential metabolism compared to normal cells.
If different metabolism between normal and malignant
cells may partially explain the preferential effect of
DNMT inhibitors on tumor cells [167], the differential
genes expression that these inhibitors induce in different
cellular sub-populations is equally relevant. Karpf and
coworker conducted a genomic analysis of gene expres-
sion modifications upon decitabine treatment both in
normal and cancerous cell lines. In their analysis the
authors concluded that decitabine (i) elicited changes in
a limited number of genes, (ii) regulated gene expression
similarly between normal and cancer cells, and (iii)
changes in the expression of specific genes required the
presence of transcriptional activators competent for acti-
vation of the target promoter [168,169]. However, if the
differences in gene expression patterns between normal
and malignant cells upon DNMT inhibitors seem to be
less marked than previously seen, the selective activation
of specific genes in tumor cells is clearly documented in
literature. In this regard, decitabine leads to the selective
activation of specific genes only in tumor cells opening
to the intriguing hypothesis that DNMT inhibitors may
increase the therapeutic index of specific antitumor stra-
tegies consenting of targeting the gene products differ-
entially expressed in tumor cells [169].
Xerostomia is a common complication of radiotherapy
on head and neck cancer due to irreparable damage
caused to the salivary glands if they are included in the
radiation fields. This side effect is perceived negatively
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by many patients with a significant impact on their
quality of life. This condition is partially due to the
death of a significant number of glandular ductal cells,
which if not replaced, result in a significant decrease in
the amount of produced saliva. Motegi and coworkers
examined the mechanism by which immortalized nor-
mal human salivary gland ductal cells acquire the ability
to express Aquaporin 5 (AQP5) and secrete fluid in
response to decitabine treatment [170]. AQP5 is a water
channel protein and its role in the generation of saliva,
tears and pulmonary secretion is well documented.
These authors suggest that decitabine resulted in AQP5
gene expression in human salivary gland ductal cells
(NS-SV-DC cells) affecting the water permeability by
increasing the transepithelial net fluid secretion of sur-
viving ductal cells. However, the improvement in the
efficiency of transepithelial fluid secretion may be of
limited value if the noxa patogena holds over the
response of normal tissue is the production of fibrosis
that results in to the complete loss of tissue function.
Table 2 Clinical toxicity
5-Azacitidine Decitabine
General Pyrexia, fatigue, weakness, rigors, pain in limb, back pain,
contusion, dizziness, erythema, chest pain, epistaxis, myalgia,
decreased weight, abdominal pain, aggravated fatigue,
abdominal tenderness, insomnia, malaise, pain, upper abdominal
pain, night sweats, lethargy, peripheral swelling, transfusion
reaction, abdominal distension, syncope, chest wall pain,
hypoesthesia, post procedural pain, general physical health
deterioration, systemic inflammatory response.
Pyrexia, peripheral edema, rigors, edema, pain, lethargy,
tenderness, fall, chest discomfort, intermittent pyrexia, malaise,
crepitations.
Local Injection site erythema, injection site pain, injection site bruising,
injection site reaction, injection site pruritus, injection site
granuloma, injection site pigmentation changes, injection site
swelling.
Erythema, catheter site pain, and injection site swelling.
Cardiovascular Cardiac murmur, hypotension, pulmonary edema.
Respiratory cough, dyspnea, nasopharyngitis, exertional dyspnea, productive
cough, pneumonia, lung crackles, rhinorrhea, rales, wheezing,
decreased breath sounds, pleural effusion, postnasal drip,
rhonchi, nasal congestion, atelectasis, exacerbated dyspnea,
sinusitis, hemoptysis, lung infiltration, pneumonitis, respiratory
distress
cough, pharyngitis, lung crackles, decreased breath sounds,
hypoxia, rales, postnasal drip.
Musculoskeletal arthralgia, muscle cramps, aggravated bone pain, muscle
weakness, and neck pain.
arthralgia, limb pain, back pain, chest wall pain, musculoskeletal
discomfort, myalgia
Hematologic anemia, thrombocytopenia, leukopenia, neutropenia, febrile
neutropenia, hypokalemia, post procedural hemorrhage,
aggravated anemia, agranulocytosis, bone marrow depression,
bone marrow failure, pancytopenia, and splenomegaly.
neutropenia, thrombocytopenia, anemia, febrile neutropenia,
leukopenia, lymphadenopathy, and thrombocythemia.
Gastrointestinal nausea, vomiting, diarrhea, constipation, anorexia, pharyngitis,
appetite decreased, gengival bleeding, oral mucosal petechiae,
stomatitis, dyspepsia, hemorrhoids, loose stools, dysphagia,
mouth hemorrhage, tongue ulceration, diverticulitis,
gastrointestinal hemorrhage, melena, perirectal abscess
nausea, constipation, diarrhea, vomiting, abdominal pain, oral
mucosal petechiae, stomatitis, dyspepsia, ascites, gingival
bleeding, hemorrhoids, loose stools, tongue ulceration,
dysphagia, oral soft tissue disorder, lip ulceration, abdominal
distension, abdominal pain upper, gastroesophageal reflux
disease, glossodynia.
Dermatologic ecchymosis, petechiae, skin lesions, rash, pruritus, increased
sweating, urticaria, dry skin, skin nodule, pyoderma
gangrenosum, pruritic rash, and skin induration.
ecchymosis, rash, erythema, skin lesion, pruritus, alopecia,
urticaria, and facial swelling.
Immunologic Infections and infestations such as pneumonia, cellulitis, candidal
infection, catheter related infection, urinary tract infection,
staphylococcal infection, oral candidiasis, sinusitis, bacteremia.
Nervous
System
headache, convulsions, intracranial hemorrhage. headache, dizziness, hypoesthesia, insomnia, confusional state,
anxiety.
Others pallor, pitting edema, lymphadenopathy, hematoma, cellulitis,
infections and infestations including herpes simplex, limb
abscess, bacterial infection, blastomycosis, injection site infection,
Klebsiella sepsis, streptococcal pharyngitis, Klebsiella pneumonia,
sepsis, Staphylococcal bacteremia, Staphylococcal infection,
neutropenic sepsis, septic shock, toxoplasmosis, genitourinary
infection, hematuria.
vascular disorders such as petechiae, pallor, hematoma,
increased blood alkaline phosphatase, aspartate
aminotransferase, blood urea, blood lactate dehydrogenase,
blood bicarbonate, decreased blood albumin, blood chloride,
protein total, blood bicarbonate, blood bilirubin, hyperglycemia,
hypoalbuminemia, hypomagnesemia, hypokalemia,
hyponatremia, decreased appetite, anorexia, hyperkalemia,
dehydration, hyperbilirubinemia, transfusion reactions, blurred
vision, dysuria, urinary frequency.
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Therefore, drugs capable of reducing the fibrinogenic
potential of specific treatments are of value in clinical
setting.
Some authors documented that DNA methylation
exert epigenetic control over fribrinogenesis and wound
healing. These events need a process of cell transdiffer-
entiation of resident cells to stellate cells, a particular
subtype of myofibroblast, which seems to be a common
process in the majority of soft tissues. Myofibroblasts
are highly profibrinogenic and produce proinflammatory
mediators (IL-6, MCP-1, PFGF, TGFb-1) resulting in
the secretion of a large quantities of collagen I and III
[171]. MeCP2 is a methyl-CpG-binding protein that has
the potential to exert regulation over the expression of
multiple genes via its interaction with methylated DNA.
MeCP2 is a repressor of IkBa which is required for
transdifferentiation and profibrinogenic activity of stel-
late cells. Another important mediator of transdifferen-
tiation and fribrinogenesis is PPARg whose
transcriptional silencing activity is required for conver-
sion of hepatic stellate cells to myofibroblast [172].
Forced expression of PPARg in hepatic myofibroblast
results in reversing the transdifferentiation and profibri-
nogenic potential of stellate cells with down-regulation
of type I collagen, loss of proliferation, and reacquisition
of their adipogenic characteristics. Experimental data
suggest that MeCP2 is recruited to the IkBa promoter
and decitabine treatment modulating epigenetically the
expression these mediator exerts control over key fibri-
nogenic and inflammatory transcriptional regulators
reducing greatly the fibrogenic potential of stellate cells
[173].
Another significant property of DNMT inhibitors is
their capability to act as antioxidants under specific bio-
logical setting. This property is very important, espe-
cially in conditions where an excess of free radicals
results in tissue damage. EGCG is a major element of
green tea with a documented activity as DNMT inhibi-
tor. Conflicting data are available in literature on the
effect of EGCG on normal and tumoral cells. In an
immortalized normal breast epithelial cell line
(MCF10A), EGCG induced growth arrest prior to the
cell cycle restriction point, with elevated p21, hypopho-
sphorylation of Rb, and decreased cyclin D1, suggesting
that higher concentrations of EGCG may be toxic to
normal mammary epithelial cells [174]. However, EGCG
may have both antioxidant and prooxidative activities
involved in redox cycling and quinone formation [175]
and may induce oxidative stress in vivo [176,177].
Cysteine conjugates, indicative of reactive species devel-
opment, have been detected after 200 and 400 mg/kg i.
p. EGCG [178]. EGCG was also reported to be capable
of inducing liver, kidney and gastrointestinal toxicity
which seemed to be correlated with bioavailability of
EGCG [176,179]. Different results were documented by
Yamamoto and his group [180] since new mechanisms
by which EGCG may act differentially in tumor and
normal cells were identified. In humans, EGCG is
rapidly absorbed through the oral mucosa and secreted
back into the oral cavity by saliva, suggesting that sali-
vary glandular cells may tolerate high concentrations of
EGCG [181]. Accordingly, this evidence suggests that
EGCG may differentially affect oxidative status and may
act as either a ROS inducer or a ROS suppressor
depending upon the cell type [182]. EGCG concentra-
tions higher than plasma Cmax do not produce ROS in
cells derived from the normal epidermis and oral cavity
but rather protect these cells by decreasing ROS pro-
duction. Mechanisms responsible for the differential
effects could rely on distinctive signal pathways activated
by EGCG in a tissue-specific manner. High concentra-
tion of EGCG failed to produce ROS in normal epider-
mal keratinocytes, and immortalized normal salivary
gland cells. In contrast, EGCG elevated ROS levels upon
treatment in a dose-dependent manner in oral carci-
noma cells. The ROS levels were significantly higher in
the tumor cell lines that possessed low catalase activity.
Therefore, EGCG may potentially simultaneously
enhance tumor cell death rate and protect normal cells
from chemo/radiation-induced oxidative stress in
tumors such as skin and head neck [182].
If uncertainty exists regarding the effect of DNMT
inhibitors on normal tissues, scanty direct evidence
exists regarding the biological effects these inhibitors
have in combination with chemotherapy or ionizing
radiation. Clinical data indicate that, when decitabine is
administered in association with cisplatin in subjects
with advanced squamous cell carcinoma of the cervix, a
significant hematological toxicity is documented [183].
Recent study reported interesting evidence of biologi-
cal interaction of a DNMT inhibitor with chemotherapy.
In this report 5-Aza was combined with cisplatin in
order to measure the improvement in the therapeutic
index of these two drugs. Interestingly, 5-Aza prevented
the nephrotoxicity related to cisplatin, which was further
related with the lowering in the levels of BUN and crea-
tinine in the murine model. The mechanism by which
5-Aza decreased the nephrotoxicity involved the reduc-
tion of the levels of mediators such as metallothioneins,
which are able to induce oxidative stress or indirectly
activate gene responsible for preventing oxidative stress.
This represents the first evidence that an epigenetic
treatment with a DNMT inhibitor reduces the toxicity
related to chemotherapy [184]. A single study dealing
with the combination of decitabine with ionizing radia-
tion reports in a differentiated effect in terms of growth
inhibition normal and cancerous cells [185]. When deci-
tabine was combined with radiation no significant
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synergism in terms of growth inhibition was found on
human fibroblasts. On contrary, irradiation alone
resulted in a significant decrease in the proliferation of
normal fibroblasts, suggesting that decitabine signifi-
cantly modified cellular response to irradiation.
Off-target effects of DNMT inhibitors and potential
contribution to radiosensitization
The mechanisms by which DNMT inhibitors exert their
effects on cells may be divided into those related to
DNMT inhibitors and those not related to demethyla-
tion of DNA. The latter mechanisms may be defined as
off-target effects and although observed at higher con-
centrations may substantially contribute to the antitu-
mor properties of nucleoside analogues alone or in
combination with chemotherapy or ionizing radiation.
Numerous chemicals as well as radiation can lead to
covalent protein-DNA adducts. 5-Aza, one of the most
important nucleoside analogue, leads to protein-DNA
adducts. 5-Aza is a cytidine analogue in which carbon-5
(C5) of the pyrimidine ring is replaced with nitrogen.
Normally, a DNA cytosine-C5 methyltransferase
(MTase) acts on cytosine residue in its recognition
sequence by covalent binding to C6, and then transfer-
ring the methyl group from S-adenosylmethionine to
C5; the covalent protein-DNA adduct is then reversed
and the enzyme dissociates from the DNA [186]. 5-Aza
substitution at target cytosine interferes with the reac-
tion cycle and results in long-lived or irreversible
MTase-DNA adduct. A major consequence of 5-Aza
treatment is loss of cytosine MTase activity [186]. In
mammalian cells, 5-Aza results in defective tRNA and
rRNAs and inhibits protein synthesis [187]. Additionally,
decitabine results in the induction of p53 DNA damage
response, proposed to be dependent on formation of
MTase adducts [188]. Covalent protein-DNA adducts or
tightly bound proteins represent a major challenge to
the DNA replication machinery. DNA replication forks
can be blocked in vivo by replication termination com-
plexes [189]. As previously described, scanty evidences
indicate that nucleoside analogues may be efficient
radiosensitizers. The cytotoxic mechanisms of nucleo-
side analogues may potentiate the effects of ionizing
radiation for several theoretical reasons. First, as DNA
synthesis inhibitors, nucleoside analogues have a poten-
tial to inhibit the repair of genomic damage induced by
ionizing radiation. Second, because they are preferen-
tially cytotoxic to proliferative cells, these analogues may
decrease the number of tumor clonogens and thus slow
down cell repopulation during fractionated radiotherapy.
Tumor shrinkage induced by these compounds may
improve tumor oxygenation and counter the detrimental
effect of tumor hypoxia on radiation response. Third, a
nucleoside analogue with DNA chain terminator
property may, following their incorporation into the
DNA repair patch, trigger an apoptotic response similar
to that observed during the replication phase. Since
DNA damage is induced in all phase of the cell cycle by
radiation, this mechanism offers the prospect of extend-
ing the cytotoxicity of these analogues to non-S-phase
cells. Due to the very low number of studies facing this
topic the aforementioned mechanisms are all putative
and specific experimental studies in vitro and in vivo
settings should be performed in order to confirm these
hypotheses.
Combination of DNMT inhibitors with HDAC inhibitors
Due to their relative antitumor selectivity DNMT inhibi-
tors have been used in combination with HDAC inhibi-
tors. Recently, there have been several excellent reviews
of the histone deacetylase inhibitors (HDACIs) field
used as a therapeutic option alone or in association with
a variety of novel and conventional anticancer agents
[190-192]. Optimal re-expression of methylated genes
such as tumor suppressor or other cancer relevant genes
following the serial application of a DNA methyltrans-
ferase inhibitor followed by an HDAC inhibitor created
significant interest in combination epigenetic therapy.
Among these p16INK4A and p14INK4b, Apaf-1 and
caspase-8 are efficiently re-expressed when DNMT inhi-
bitors and HDACIs are combined [190-192]. DNMT
and a group of methyl-cytosine binding proteins, e.g.,
MeCP2, can also recruit and direct HDACs to the chro-
matin associated with silenced genes. Combined treat-
ment with a DNMT inhibitor and HDACI has been
shown to be superior in de-repressing silenced tumor
suppressor genes, as well as in inducing increased
growth inhibition, differentiation and apoptosis of can-
cerous cells. The best results in de-repressing silenced
genes are observed when DNMT inhibitors are used
first at relatively low doses followed by exposure to the
HDACIs.
Conclusions and Future Directions
No doubt exists that combining traditional cancer ther-
apy with epigenetic modulators and reversing the
changes of DNA methylation pattern holds a huge
potential for successful treatment of haematological and
solid malignancies. There are a number of important
steps that need to be accomplished on the path towards
efficient epigenetic therapy. Firstly, it is important to
gain more insight into the diverse molecular mechan-
isms of the epi-drugs available today. A body of experi-
mental evidences suggests that DNMT inhibitors may
serve as efficient chemo- and radiosensitizers in solid
tumors. However, the observation reported need more
support in order to indicate intimate molecular mechan-
isms of chemo- and radiosensitization. Additionally, the
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understanding of different mechanisms as well as the
long term safety of DNMT inhibitors on normal cells
alone or in combination with standard treatments
remains very limited and requires further research
efforts. Although clinical and preclinical data indicate a
substantial toxicity of these inhibitors, other evidence
seems to suggest that these drugs may have potential in
reducing toxicity under specific conditions. Therefore,
the future goal is to indentify compounds able to
enhance the therapeutic index and protect the non
malignant tissues from side effects. Finally, other precli-
nical data suggest that the sensitizing effects of DNMT
inhibitors seem to depend on the epigenetic modulation
of a wide array of genes. A non negligible part of this
effect may be related to the off-target mechanisms.
Future research will focus on establishing clinically rele-
vant combinations of DNMT inhibitors and conven-
tional cancer therapies. In particular, a longstanding
interest exists in the development of molecules that can
modify cellular responses to radiation and chemother-
apy. The future perspectives lie in identifying more simi-
lar compounds and elucidating their mechanisms of
action in order to develop more effective cancer thera-
pies and treatments.
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